Blade Air Mobility's Recent Developments
Blade Air Mobility Inc (NASDAQ: BLDE) has recently made headlines with significant changes in its business direction. The company announced a deal with Joby Aviation (NYSE: JOBY) to sell its passenger mobility segment for up to $125 million. This development initially produced a positive reaction in the stock markets, propelling BLDE stock up by 30%. Following this announcement, the company plans to transform into a dedicated medical logistics operator and will rebrand itself as Strata Critical Medical.
However, subsequent financial reports revealed a mixed bag of results. While Blade surpassed revenue expectations, it reported a negative earnings per share of five cents; this was a cent lower than what analysts had anticipated with their projections.
This earnings report highlighted the transformative potential of Blade's new focus and its critical niche in the business services sector. Nonetheless, the company's journey towards profitability may be prolonged, especially as it navigates the implications of its new partnership with Joby.
Understanding the Business Structure
Blade's operations are comprised of two primary divisions: the Medical division and the Blade Passenger division. The medical segment includes the MediMobility Organ Transport service, which is recognized as the largest dedicated air transporter of human organs for transplant purposes in the nation.
Current earnings show that almost 60% of Blade's revenues come from its medical division, contributing 84% of its earnings before interest, taxes, depreciation, and amortization (EBITDA). In the latest quarter, the medical segment also demonstrated healthy growth, with an 18% year-over-year increase. In contrast, the passenger division saw a decline of 8% year-over-year, emphasizing the need for a shift in focus.
Aiming for Profitability and Growth
In discussing the Joby agreement, Blade's management expressed optimism about future growth. The executives highlighted their expectations for continued organic growth in the forthcoming years. They also mentioned plans for strategic acquisitions, backed by approximately $200 million in cash from the sale of its passenger division.
Ultimately, this transition is geared towards creating a more efficient business with predictable cash flows, concentrating on non-emergency medical transport, organ logistics, and time-sensitive healthcare logistics. The management's insights suggest that this approach may offer a more stable financial outlook, especially compared to the volatility associated with urban air travel markets.
Evaluating the Risks Involved
The agreement to sell Blade's passenger division to Joby, valued at up to $125 million, will be entirely stock-based, adding a level of uncertainty to the deal's final valuation. On a recent earnings call, the CEO, Rob Wiesenthal, conveyed confidence in the transaction's successful closure, projected within the first half of 2026. This extended timeline does raise concerns about potential fluctuations in stock prices, particularly for a startup like Joby, which is still firmly in its developmental phase.
Such a structure introduces the risk that variations in Joby’s stock price could ultimately affect Blade's payout from the transaction. As the completion date nears, the price volatility in the stock markets will play a vital role in determining the overall success of this strategic move.
Understanding the Future of BLDE Stock
Although the anticipated future of Blade as a streamlined, profitable medical logistics provider is encouraging, there is a significant gap between the current position and that potential. Blade estimates the organ logistics market to be around $1 billion, of which it holds approximately 30% market share.
This shift in business model may not align with the original motivations of many investors who were initially drawn to the air mobility prospect. While the new company structure may yield short-term financial stability and growth, the long-term upside could be less appealing for those hoping to profit from air mobility innovation.
Until the passenger business is completely divested, BLDE stock might experience a cautious approach from investors, leading to a somewhat volatile trading environment. Investors who prefer a lower risk profile may decide to delay their entry into BLDE shares until closer to the deal's completion. Conversely, risk-tolerant investors may consider establishing their positions ahead of any new developments as the final details of the Joby agreement become clearer.
Frequently Asked Questions
What recent changes has Blade Air Mobility made?
Blade Air Mobility has sold its passenger mobility business to Joby Aviation and will now focus on medical logistics as Strata Critical Medical.
How much is the Joby deal worth?
The deal with Joby is valued at up to $125 million, paid in stock.
What percentage of Blade's revenue comes from the medical division?
Nearly 60% of Blade's revenue is generated from its medical division, primarily through organ transportation services.
What are the risks associated with the Joby deal?
The deal's risk includes dependence on Joby's stock performance, which can affect Blade's payout due to the stock-based payment structure.
When is the deal expected to close?
The sale of Blade’s passenger business to Joby is projected to close in the first half of 2026.
